Lon S. Schneider MD
Geriatric Psychiatry
Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of the University of Southern California Director of the California Alzheimer's Disease Center, the Department of Psychiatry Geriatric Studies Center
Join to view full profile
1520 San Pablo StSte 1652Los Angeles, CA 90033
Phone+1 323-442-6000
Fax+1 323-442-6001
Dr. Schneider is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Southern California School of MedicineMS, Applied Biometry and Epidemiology, 1995
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Psychiatry, 1978 - 1983
Drexel University College of MedicineClass of 1978
Certifications & Licensure
CA State Medical License 1979 - 2027
American Board of Psychiatry and Neurology Psychiatry- American Board of Psychiatry and Neurology Geriatric Psychiatry
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
Publications & Presentations
PubMed
- Early Retinal UCHL1 Dysregulation Coupled With Synaptic Loss Reflects Alzheimer's Disease Severity.Altan Rentsendorj, Jean-Philippe Vit, Alexandre Hutton, Yosef Koronyo, Saba Shahin
Advanced Science. 2026-08-29 - 1 citationsMethodological Considerations for Quantile Aggregation in Alzheimer Disease Trials.Michael D Flanders, Michelle Caunca, Renaud La Joie, Lon S Schneider, Sarah F Ackley
JAMA Neurology. 2026-08-01 - Neuropsychiatric symptom profile in neurocognitive disorders and their relationship with functional decline.Carolyn W Zhu, Lon S Schneider, Gregory A Elder, Laili Soleimani, Judith Neugroschl
Frontiers in Neurology. 2026-07-06
Press Mentions
Two Patients Navigate the New Alzheimer's DrugsMarch 3rd, 2025- Alzheimer's Data WithdrawnNovember 11th, 2024
- If Alzheimer's Drug Ads Had More Data, Here's What Might HappenAugust 30th, 2024
Grant Support
- FDA approved IND 29644: Multicenter Phase 1 Trial to Evaluate Safety and Immunogenicity of Preventive Tau Vaccine, AV-1980R/A, in cognitively unimpaired preclinical AD participants.INSTITUTE FOR MOLECULAR MEDICINE2025–2030
- Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.INSTITUTE FOR MOLECULAR MEDICINE2022–2027
- Safety/Tolerability/Immunogenicity of first-in-human Aβ DNA vaccine, AV-1959D Phase 1 trials in early-stage AD subjects: based on IND18953 cleared by FDA.INSTITUTE FOR MOLECULAR MEDICINE2022–2027
- Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical TrialUNIVERSITY OF ARIZONA2019–2026
- (-)-Phenserine inhibition of neuronal death in Alzheimer’s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trialUNIVERSITY OF SOUTHERN CALIFORNIA2019–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
